Nile Therapeutics, Inc.

Acquired by Capricor, Inc.

Nile Therapeutics, Inc., is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is currently focusing its efforts on developing its lead compound, cenderitide, a novel rationally-designed chimeric peptide in clinical studies for the treatment of heart failure.

*past representation